Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
Daily Voice Tolland County CT on MSN4h
FDA Approves First Non-Opioid Painkiller In 20+ Years: 'A Historic Milestone'The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...
Mohit Bansal, an analyst from Wells Fargo, assigned the Buy rating on Ironwood Pharma (IRWD – Research Report). The associated price target is ...
The Japanese conglomerate is in talks to spend up to $43 billion to boost the ChatGPT developer. Novartis expects profit and sales to grow further this year after beating analysts' expectations, ...
After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
U.S. stocks fall on Friday after the White House says Canada, Mexico and China tariffs will start Saturday. Still, major indexes finish January ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback